Alternative lengthening of telomeres: models, mechanisms and implications

被引:0
|
作者
Anthony J. Cesare
Roger R. Reddel
机构
[1] Cancer Research Unit,
[2] Childrens Medical Research Institute,undefined
[3] University of Sydney,undefined
[4] The Salk Institute for Biological Studies,undefined
来源
Nature Reviews Genetics | 2010年 / 11卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
About 10% of all cancers, including some that have a particularly poor prognosis, use the alternative lengthening of telomeres (ALT) pathway to prevent the telomere shortening that accompanies proliferation of normal cells.ALT-positive cells commonly have a number of unusual characteristics, including telomeric DNA that is separated from chromosome ends. This extrachromosomal telomeric DNA may be linear or circular.Partially single-stranded circles of telomeric DNA in which the C-rich (AATCCC)n strand is essentially intact and the G-rich (TTAGGG)n strand is gapped seem to be the best of the known markers for ALT. The quantity of this 'C-circle' DNA correlates well with the amount of ALT activity.Telomere elongation in ALT cells involves homologous recombination.The experimental evidence fits best with a model for ALT in which telomeric 3′ overhangs become extended by invading other telomeric DNA and using it as a template for DNA replication. The other telomeric DNA can be: part of the same telomere (through telomere-loop formation); in a sister chromatid; in the telomere of another chromosome; or in one of the forms of extrachromosomal telomeric DNA.Proteins that are thought to be required for ALT include the homologous recombination protein complexes MRN (which is made up of meiotic recombination 11 (MRE11, also known as MRE11A), RAD50 and Nijmegen breakage syndrome 1 (NBS1, also known as NBN)) and structural maintenance of chromosomes 5 (SMC5)–SMC6, and proteins, such as flap endonuclease 1 (FEN1), MUS81, Fanconi anaemia group D2 (FANCD2) and Fanconi anaemia group A (FANCA), that may be required for recombination-dependent restart of stalled telomeric DNA replication.Promyelocytic leukaemia (PML) bodies containing telomeric DNA are characteristic of ALT cells, and are referred to as ALT-associated PML bodies (APBs). Large APBs seem to be associated with senescence of ALT cells and sequestration of extrachromosomal DNA, but we speculate that smaller APBs may be sites at which telomere lengthening occurs.In ALT cells, many of the telomeres elicit a DNA-damage response but repress chromosome end-to-end fusions. This telomere state, which is intermediate between the fully capped and uncapped fusogenic telomere states, may reflect a structural change that is permissive for recombination-mediated telomere replication.
引用
收藏
页码:319 / 330
页数:11
相关论文
共 50 条
  • [1] Alternative lengthening of telomeres: models, mechanisms and implications
    Cesare, Anthony J.
    Reddel, Roger R.
    NATURE REVIEWS GENETICS, 2010, 11 (05) : 319 - 330
  • [2] Mechanisms of Alternative Lengthening of Telomeres
    O'Sullivan, Roderick J.
    Greenberg, Roger A.
    COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY, 2025, 17 (01):
  • [3] Alternative Lengthening of Telomeres in Pediatric Cancer: Mechanisms to Therapies
    Kent, Thomas
    Gracias, Deanne
    Shepherd, Samuel
    Clynes, David
    FRONTIERS IN ONCOLOGY, 2020, 9
  • [4] Molecular mechanisms of activity and derepression of alternative lengthening of telomeres
    Pickett, Hilda A.
    Reddel, Roger R.
    NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2015, 22 (11) : 875 - 880
  • [5] Molecular mechanisms of activity and derepression of alternative lengthening of telomeres
    Hilda A Pickett
    Roger R Reddel
    Nature Structural & Molecular Biology, 2015, 22 : 875 - 880
  • [6] Alternative lengthening of telomeres: from molecular mechanisms to therapeutic outlooks
    Jia-Min Zhang
    Lee Zou
    Cell & Bioscience, 10
  • [7] Alternative lengthening of telomeres: from molecular mechanisms to therapeutic outlooks
    Zhang, Jia-Min
    Zou, Lee
    CELL AND BIOSCIENCE, 2020, 10 (01):
  • [8] The Molecular Mechanisms and Therapeutic Prospects of Alternative Lengthening of Telomeres (ALT)
    Sohn, Eric J.
    Goralsky, Julia A.
    Shay, Jerry W.
    Min, Jaewon
    CANCERS, 2023, 15 (07)
  • [9] The Role of Alternative Lengthening of Telomeres Mechanism in Cancer: Translational and Therapeutic Implications
    Recagni, Marta
    Bidzinska, Joanna
    Zaffaroni, Nadia
    Folini, Marco
    CANCERS, 2020, 12 (04)
  • [10] A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas
    Henson, JD
    Hannay, JA
    McCarthy, SW
    Royds, JA
    Yeager, TR
    Robinson, RA
    Wharton, SB
    Jellinek, DA
    Arbuckle, SM
    Yoo, JY
    Robinson, BG
    Learoyd, DL
    Stalley, PD
    Bonar, SF
    Yu, DH
    Pollock, RE
    Reddel, RR
    CLINICAL CANCER RESEARCH, 2005, 11 (01) : 217 - 225